Milan

• A Phase 1/2 Study of MK-2870 plus EV plus Pembrolizumab in la/mUC Ended recruitment
  2023-506387-14-00 7 2024-09-24 Advanced Urothelial Carcinoma
• A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended recruitment
  2024-511038-11-00 4 2024-09-24 advanced prostate cancer
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended recruitment
  2023-509716-29-00 9 2024-09-23 Solid Tumors, Colorectal Cancer and Breast Cancer
• AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous … Ended recruitment
  2024-511195-33-00 3 2024-09-23 Gastrointestinal tract, biliary tract, or pancreatic cancers with homo
• A study to investigate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared w … Ended recruitment
  2022-500306-17-00 5 2024-09-20 Mucopolysaccharidosis type I, Hurler Syndrome
• A PHASE 1/2 STUDY EXPLORING THE SAFETY AND ACTIVITY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH CAPECITABINE AND BEVACIZUMAB IN METASTATIC … Ended recruitment
  2024-513271-41-00 4 2024-09-16 colorectal metastatic cancer
• An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended recruitment
  2023-508219-21-00 5 2024-09-12 BTC - Biliary Tract Cancer
• A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended recruitment
  2023-506769-67-00 4 2024-09-04 Moderate to Severely Active Ulcerative Colitis
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas) Ended recruitment
  2022-501452-29-00 9 2024-08-28 Metastatic Non-small Cell Lung Cancer
• A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination wit … Ended recruitment
  2023-507377-17-00 1 2024-08-28 Advanced Melanoma
• Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended recruitment
  2023-504922-20-00 5 2024-08-23 Hypercholesterolemia
• A study to investigate long-term follow-up in subjects who received BMN 270 in a prior BioMarin Clinical Trial with hemophilia A Ended recruitment
  2023-507749-27-00 6 2024-08-16 Hemophilia A
• A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended recruitment
  2023-505423-31-00 5 2024-08-08 advanced or metastatic gastric adenocarcinoma, gastroesophageal juncti
• Phase 3 Study of ALXN1850 versus Placebo in Adolescent and Adult Participants with HPP who have not previously been treated with Asfotase Al … Ended recruitment
  2023-505673-32-00 5 2024-08-05 Hypophosphatasia
• Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years Ended recruitment
  2023-504331-41-00 5 2024-08-02 Respiratory tract diseases - Wheezing, Asthma
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• Phase 2 Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma Ended recruitment
  2023-505177-32-00 4 2024-07-31 Intermediate-high -risk RCC, high-risk RCC who have undergone nephrect
• A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) Ended recruitment
  2024-512747-23-00 5 2024-07-30 Transfusion-Dependent Alpha- or Beta-Thalassemia
• A phase 2 study to investigate the efficacy and safety of CYP‑001 in combination with corticosteroids in adults with high-risk acute graft v … Ended recruitment
  2022-502673-41-01 4 2024-07-29 High-Risk Acute Graft Versus Host Disease
• Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended recruitment
  2023-507204-31-00 5 2024-07-26 Hidradenitis Suppurativa
• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended recruitment
  2023-503923-24-00 5 2024-07-22 Sjögren’s Syndrome With Moderate-toSevere Symptom State
• Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study Ended recruitment
  2023-509088-26-00 4 2024-07-22 Metastatic colorectal cancer

Showing 1,321–1,344 of 2,361 trials